References
- Williams HJ, Owen MJ, O’Donovan MC. Is COMT a susceptibility gene for schizophrenia? Schizophr Bull. 2007; 33(3): 635-461.
- Varma GS, Karadağ OF, Erdal ME, Ay Öİ, Levent N, Tekkanat Ç, et al. Katekol-O-metiltransferaz geni Vall58 Met polimorfizminin şizofreni hastalarındaki bilişsel işlevlere Tiileri. Bull Clin Psychopharmacol. 2011; 21(1): 24-32.
- Oswald LM, McCaul M, Choi L, Yang X, Wand GS. Catechol-O-methyltransferase polymorphism alters hypothalamic-pituitary-adrenal axis responses to naloxone: A preliminary report. Biol Psychiatry. 2004; 55(1): 102-105.
- Drabant EM, Hariri AR, Meyer-Lindenberg A, Munoz KE, Mattay VS, Kolachana BS, et al. Catechol O-methyltransferase val 15 8met genotype and neural mechanisms related to affective arousal and regulation. Arch Gen Psychiatry. 2006; 63(12): 1396-1406.
- van Winkel R, Henquet C, Rosa A, Papiol S, Fañanás L, De Heret M, et al. Evidence that the COMT Val158 Met polymorphism moderates sensitivity to stress in psychosis: An experience sampling study. Am J Med Genet B Neuropsychiatr Genet. 2008; 147B(1): 10-17.
- Stein MB, Fallin MD, Schork NJ, Gelernter J. COMT polymorphisms and anxiety-related personality traits. Neuropsychopharmacology. 2005; 30(11): 2092-2102.
- Lee D, Karschner EL, Milman G, Barnes AJ, Goodwin RS, Huestis MA. Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration? Drug Alcohol Depend. 2013; 130(1-3): 68-76.
- Crime UNOoDa. World Drug Report 2017: United Nations publication. Available from: https://www.unodc.org/wdr2017/index.html
- Tomiyama K, Funada M. Cytotoxicity of synthetic cannabinoids found in “Spice” products: The role of can-nabinoid receptors and the caspase cascade in the NG 108-15 cell line. Toxicol Lett. 2011; 207(1): 12-17.
- Su MK, Seely KA, Moran JH, Hoffman RS. Metabolism of classical cannabinoids and the synthetic cannabinoid JWH-018. Clin Pharmacol Ther. 2015; 97(6): 562-564.
- Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard S, Huestis MA. Synthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend. 2014; 144: 12-41.
- Vandrey R, Dunn KE, Fry JA, Girling ER. A survey study to characterize use of Spice products (synthetic cannabinoids). Drug Alcohol Depend. 2012; 120(1-3): 238-241.
- Ibrahim S, Al-Saffar F, Wannenburg T. A unique case of cardiac arrest following K2 abuse. Case Rep Cardiol. 2014;2014:120607.
- Johnson LA, Johnson RL, Alfonzo C. Spice: A legal marijuana equivalent. Mil Med. 2011; 176(6): 718-720.
- Barratt MJ, Cakic V, Lenton S. Patterns of synthetic cannabinoid use in Australia. Drug Alcohol Rev. 2013; 32(2): 141-146.
- Hoyte CO, Jacob J, Monte AA, Al-Jumaan M, Bronstein AC, Heard KJ. A characterization of synthetic cannabinoid exposures reported to the National Poison Data System in 2010. Ann Emerg Med. 2012; 60(4): 435-438.
- Evren C, Ögel K. Alkol/madde bagimlilarinda dissosiyatif belirtiler ve çocukluk çagi travmasi, depresyon, anksiyete ve alkol/madde kullanimi ile iliskisi. (Dis-sociative symptoms among alcohol and substance dependents and its relationships with childhood trauma history, depression, anxiety, and alcohol/substance use.) Anatolian J Psychiatry. 2003; 4(1): 30.
- Karayiorgou M, Altemus M, Galke BL, Goldman D, Murphy DL, Ott J, et al. Genotype determining low catechol-O-methyltransferase activity as a risk factor for obsessive-compulsive disorder. Proc Natl Acad Sci USA. 1997; 94(9): 4572-4575.
- Klemetsdal B, Straume B, Giverhaug T, Aarbakke J. Low catechol-O-methyltransferase activity in a Saami population. Eur J Clin Pharmacol. 1994; 46(3): 231-235.
- Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE, et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA. 2001; 98(12): 6917-6922.
- Lachman HM, Papolos DF, Saito T, Yu Y-M, Szumlanski CL, Weinshilboum RM. Human catechol-O-methyltransferase pharmacogenetics: Description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics. 1996; 6(3): 243-250.
- Chen J, Lipska BK, Halim N, Ma QD, Matsumoto M, Melhem S, et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): Effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet. 2004; 75(5): 807-821.
- Tunbridge E, Weickert C, Kleinman J, Herman M, Chen J, Kolachana B, et al. Catechol-o-methyltransferase enzyme activity and protein expression in human prefrontal cortex across the postnatal lifespan. Cereb Cortex. 2007; 17(5): 1206-1212.
- Craddock N, O’Donovan MC, Owen MJ. Genes for schizophrenia and bipolar disorder? Implications for psychiatric nosology. Schizophr Bull. 2006; 32(1): 9-16.